Floatz logo

Avelumab

Stage IVB Prostate Cancer AJCC v8

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Stage IVB Prostate Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Fluciclovine
NRG Oncology
Phase 4BB
VIPIVOTIDE TETRAXETAN
Mayo Clinic
Phase 3BB
Hyaluronidase zzxf
Mayo Clinic
Phase 2B
CEP 11981
Barbara Ann Karmanos Cancer Institute
Phase 2CCC
TECHNETIUM TC-99M CATION, UNSPECIFIED
University of California, San Francisco
Phase 2CCC

View all 14 →

Same molecule, other indications

Avelumab is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
urothelial carcinomaDormant
B
Indicative ·
58 / 100
View asset →
bladder transitional cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →